Search Results - "Jouffroy, Claire"

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer by Conroy, Thierry, Hammel, Pascal, Hebbar, Mohamed, Ben Abdelghani, Meher, Wei, Alice C, Raoul, Jean-Luc, Choné, Laurence, Francois, Eric, Artru, Pascal, Biagi, James J, Lecomte, Thierry, Assenat, Eric, Faroux, Roger, Ychou, Marc, Volet, Julien, Sauvanet, Alain, Breysacher, Gilles, Di Fiore, Frédéric, Cripps, Christine, Kavan, Petr, Texereau, Patrick, Bouhier-Leporrier, Karine, Khemissa-Akouz, Faiza, Legoux, Jean-Louis, Juzyna, Béata, Gourgou, Sophie, O’Callaghan, Christopher J, Jouffroy-Zeller, Claire, Rat, Patrick, Malka, David, Castan, Florence, Bachet, Jean-Baptiste

“…In a prospective, randomized trial involving patients with resected pancreatic cancer, adjuvant combination chemotherapy with FOLFIRINOX resulted in a median…”
Get full text

Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial by Ychou, Marc, Rivoire, Michel, Thezenas, Simon, Guimbaud, Rosine, Ghiringhelli, Francois, Mercier-Blas, Anne, Mineur, Laurent, Francois, Eric, Khemissa, Faiza, Chauvenet, Marion, Kianmanesh, Reza, Fonck, Marianne, Houyau, Philippe, Aparicio, Thomas, Galais, Marie-Pierre, Audemar, Franck, Assenat, Eric, Lopez-Crapez, Evelyne, Jouffroy, Claire, Adenis, Antoine, Adam, René, Bouché, Olivier

“…Background Colorectal cancer (CRC) patients have a better prognosis if metastases are resectable. Initially, unresectable liver-only metastases can be…”
Get full text

Rationale and Design of the IROCAS Study: Multicenter, International, Randomized Phase 3 Trial Comparing Adjuvant Modified (m) FOLFIRINOX to mFOLFOX6 in Patients With High-Risk Stage III (pT4 and/or N2) Colon Cancer—A UNICANCER GI-PRODIGE Trial by Bennouna, Jaafar, André, Thierry, Campion, Loïc, Hiret, Sandrine, Miglianico, Laurent, Mineur, Laurent, Touchefeu, Yann, Artru, Pascal, Asmis, Timothy, Bouché, Olivier, Borde, Florence, Kavan, Petr, Lam, You-Heng, Rajpar, Laetitia-Shana, Emile, Jean-François, Jouffroy, Claire, Gill, Sharlene, Taïeb, Julien

“…According to the IDEA trial, 6-month adjuvant chemotherapy should remain the treatment standard in stage III T4 or N2 colon cancer. The relatively poor…”
Get full text

Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial by Conroy, Thierry, Bosset, Jean-François, Etienne, Pierre-Luc, Rio, Emmanuel, François, Éric, Mesgouez-Nebout, Nathalie, Vendrely, Véronique, Artignan, Xavier, Bouché, Olivier, Gargot, Dany, Boige, Valérie, Bonichon-Lamichhane, Nathalie, Louvet, Christophe, Morand, Clotilde, de la Fouchardière, Christelle, Lamfichekh, Najib, Juzyna, Béata, Jouffroy-Zeller, Claire, Rullier, Eric, Marchal, Frédéric, Gourgou, Sophie, Castan, Florence, Borg, Christophe, Borg, Christophe, Etienne, Pierre-Luc, Rio, Emmanuel, Mesgouez-Nebout, Nathalie, François, Éric, Vendrely, Véronique, Conroy, Thierry, Artignan, Xavier, Bouché, Olivier, Gargot, Dany, Boige, Valérie, Bonichon-Lamichhane, Nathalie, Louvet, Christophe, Morand, Clotilde, de la Fouchardière, Christelle, Ronchin, Philippe, Seitz, Jean-François, Corbinais, Stéphane, Maillard, Emmanuel, Noirclerc, Monique, El Hajbi, Farid, Villing, Anne-Laure, Bécouarn, Yves, Foong Fat Lam Kam Sang, Lam, Artru, Pascal, Bachet, Jean-Baptiste, Hocine, Fayçal, Ligeza-Poisson, Catherine, Vautravers, Claire, Ben Abdelghani, Meher, Aparicio, Thomas, Desot, Elise, Marquis, Isabelle

“…Treatment of locally advanced rectal cancer with chemoradiotherapy, surgery, and adjuvant chemotherapy controls local disease, but distant metastases remain…”
Get full text

814 DT-9081, a selective EP4 receptor antagonist which synergizes with immune checkpoint inhibitors to induce complete responses in syngeneic murine cancer models by Blayo, Anne-Laure, Jouffroy-Zeller, Claire, Lenne, Nathalie, Nafia, Imane, Zerr, Patricia, Schann, Stéphan, Leroy, Xavier

“…BackgroundElevated levels of Prostaglandin E2 (PGE2), an eicosanoid synthesized by the cyclooxygenase-2 (COX-2), exert strong immunosuppressive effects in the…”
Get full text

Neoadjuvant chemoradiation (CRT) for locally advanced rectal cancer (LARC) with or without oxaliplatin (OX): Individual patient data (IPD) meta-analysis of three randomized controlled trials (RCTs) with subgroup analyses of age cohorts by Fontana, Elisa, Zichi, Clizia, Smyth, Elizabeth Catherine, Mauer, Murielle E., Roedel, Claus, Fokas, Emmanouil, Hofheinz, Ralf Dieter, Arnold, Dirk, Schmoll, Hans-Joachim, Van Cutsem, Eric, Haustermans, Karin, Stein, Alexander, Gerard, Jean-Pierre, Conroy, Thierry, Jouffroy-Zeller, Claire, Moehler, Markus H., Lordick, Florian, Ben-Aharon, Irit, Di Maio, Massimo

“…Abstract only 4074 Background: Neoadjuvant CRT with fluoropyrimidine (FP) is standard treatment for LARC, which is increasing in younger patients (pts). RCTs…”
Get full text

Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas by Conroy, Thierry, Hammel, Pascal, Hebbar, Mohamed, Ben Abdelghani, Meher, Wei, Alice Chia-chi, Raoul, Jean-Luc, Chone, Laurence, Francois, Eric, Artru, Pascal, Biagi, James Joseph, Lecomte, Thierry, Assenat, Eric, Faroux, Roger, Ychou, Marc, Volet, Julien, Sauvanet, Alain, Jouffroy-Zeller, Claire, RAT, Patrick, Castan, Florence, Bachet, Jean-Baptiste

“…Abstract only LBA4001 Background: FOLFIRINOX is more effective than gem as first-line treatment in metastatic pancreatic cancer for patients (pts) with good…”
Get full text

Induction chemotherapy (CT) with FOLFIRINOX or FOLFOX/FOLFIRI, plus cetuximab (CET) or bevacizumab (BEV) (by RAS status), in patients (pts) with primarily unresectable colorectal liver metastases (CRLM): Results of the randomized UNICANCER PRODIGE 14-ACCORD 21 (METHEP-2) trial by Ychou, Marc, Rivoire, Michel, Thezenas, Simon, Guimbaud, Rosine, Ghiringhelli, Francois, Mercier Blas, Anne, Mineur, Laurent, Francois, Eric, Khemissa, Faiza, Chauvenet, Marion, Bécouarn, Yves, Houyau, Philippe, Aparicio, Thomas, Galais, Marie Pierre, Audemar, Franck, Assenat, Eric, Adenis, Antoine, Jouffroy-Zeller, Claire, Adam, Rene, Bouche, Olivier

“…Abstract only…”
Get full text

FOLFIRINOX plus cetuximab (CET) or bevacizumab (BEV) in patients (pts) with initially unresectable colorectal liver metastases (CRLM) with BRAF mutated (mut) tumors: A subgroup analysis of the UNICANCER PRODIGE 14-ACCORD 21 (METHEP2) trial by Lopez-Crapez, Evelyne, Adenis, Antoine, Thezenas, Simon, Assenat, Eric, Francois, Eric, Guimbaud, Rosine, Chauvenet, Marion, Khemissa, Faiza, Audemar, Franck, Suc, Etienne, Rivoire, Michel, Ghiringhelli, François, Mercier-Blas, Anne, Mineur, Laurent, Becouarn, Yves, Houyau, Philippe, Stanbury, Trevor, Jouffroy-Zeller, Claire, Bouche, Olivier, Ychou, Marc

“…Abstract only…”
Get full text

PRODIGE 52-UCGI 29-CCTG/CO.27 (IROCAS): A multicenter, international, randomized phase III trial comparing adjuvant modified (m)FOLFIRINOX to mFOLFOX6 in patients with high-risk stage III (pT4 and/or N2) colon cancer (a UNICANCER GI-PRODIGE trial) by Bennouna, Jaafar, Andre, Thierry, Miglianico, Laurent, Campion, Loic, Mineur, Laurent, Lam, You Heng, Hiret, Sandrine, Artru, Pascal, Bouche, Olivier, Borde, Florence, Aleba, Albert, Rajpar, Laetitia-Shanna, Rebischung, Christine, Touchefeu, Yann, Kavan, Petr, Gill, Sharlene, Asmis, Tim, Jouffroy-Zeller, Claire, Emile, Jean-François, Taieb, Julien

“…Abstract only…”
Get full text